Rapid recovery of lymphocytes after T-cell depleted hematopoietic SCT (HSCT) protects from relapse of myeloid malignancies. Whether lymphocyte reconstitution has a similar role after non-manipulated transplantation is controversial. We assessed numbers of CD4 and CD8 T-cells, natural killer (NK) cells and B-cells, before and 1, 3, 6, 12 and 24 months after T-cell replete transplantation in 345 patients. Lymphocyte subset counts up to 6 months post transplant had no effect on relapse. Elevated number of NK cells 12 months post transplant protected from relapse. As a novel finding, early recovery of NK cells was associated with significant protection from TRM already at the 3 and 6 months time points (P ¼ 0.03, P ¼ 0.02). In Cox multivariable models, patients with NK cells above 150/lL were significantly protected from TRM (hazard ratio (HR) 0.45, 95% confidence interval (95% CI) 0.21-0.95, P ¼ 0.03), an effect comparable in magnitude with that of carrying 4200 CD4 T-cells/lL (HR 0.37, 95% CI 0.19-0.74, P ¼ 0.005). CD8 T-cell and B-cell recovery did not affect the rates of relapse or TRM. Early reconstitution of NK cells and CD4 T-cells in patients undergoing T-cell replete HSCT independently protected from TRM. Only a weak protection from disease relapse was noted for patients with high numbers of NK cells, and this occurred only late after transplantation.
Introduction
Allogeneic hematopoietic SCT relies on graft-vs-tumor effects for its curative potential. Accordingly, early recovery of donor derived lymphocytes has been associated with improved survival. [1] [2] [3] [4] Depending on the type of transplant regimen used, improved survival in patients with rapid lymphocyte recovery is a consequence of reduced rates of relapse 5 or protection from TRM. 6 In the setting of T-cell-depleted transplantation, the protective effects have been attributed to early reconstitution of natural killer (NK) cells, the first lymphocyte subset to reconstitute after this transplant type. 7 In T-cell replete transplantation, several questions remain open: it is undefined which lymphocyte subsets have the greatest influence on transplant outcome; it is unclear whether rapid lymphocyte recovery protects from disease relapse or from TRM; the association of lymphocyte recovery and the treatment for graft-vs-host disease is unclear, with a previous study suggesting that lymphocytopenia at day 30 is associated with both steroid treatment and a higher risk of disease relapse. 8 Finally, most data on lymphocyte recovery and transplant outcome stem from patients transplanted using myeloablative conditioning regimens and therefore, the role of lymphocyte subset recovery after transplantation with reduced intensity conditioning regimens is unclear. Interestingly, a small recently published study in 25 patients found no association of lymphocyte reconstitution and transplant outcome after reduced intensity conditioning regimen transplantation. 9 To answer these questions, we retrospectively analyzed lymphocyte subset (that is, CD4 T-cell, CD8 T-cell, NK cell and B-cell) recovery in a large cohort of patients undergoing T-cell replete allogeneic hematopoietic SCT and correlated lymphocyte subset reconstitution with transplant outcome.
Patients and methods

Transplant procedure
We analyzed 345 patients undergoing T-cell replete allo-SCT at Basel University Hospital between 1998 and 2009. The majority of patients underwent myeloablative conditioning regimens (N ¼ 256), whereas 89 patients were transplanted after non-myeloablative conditioning. All patients were treated for malignant hematological conditions. Donors were HLA-identical siblings, HLA-matched or one-Ag mismatched other related donors, or unrelated donors. All patients received unmanipulated, T-cell replete allografts. Graft-vs-host disease prophylaxis was with CsA and either MTX or mycophenolate mofetil. Further patient and transplant characteristics are summarized in Table 1 . All patients gave written informed consent to the transplant procedure and to analysis of outcome data.
Flow cytometry
Lymphocyte sub-populations were systematically assessed before the start of the conditioning regimen, as well as 1, 3, 6, 12 and 24 months after transplantation. After 2005, lymphocytes were immunolabeled using BD Trucount beads (BD Biosciences, San Jose, CA, USA) and BD Multitest reagents (BD Biosciences) with an Ab combination of CD3-FITC/ CD16-phycoerythrin þ CD56-phycoerythrin/CD45-peridin chlorophyl protein/CD19-allophycocyanin and CD3-FITC/ CD8-phycoerythrin/CD45-peridin chlorophyl protein/CD4-allophycocyanin, according to the recommendations of the manufacturer. 10 Samples were analyzed within 2 h on a FACSCalibur (BD Biosciences). Dot plots were analyzed using FACS Multiset software (BD Biosciences). Before 2005, lymphocyte sub-populations were assessed in whole blood by a dual platform, three stage process: (i) the WBC count, (ii) the percentage of WBCs that are lymphocytes and (iii) the percentage of lymphocytes that are T-, B-or NKcells. The last stage in the process was performed by flow cytometry. Lymphocytes were immunolabeled and analyzed using a procedure similar to that described above for the single-platform method but without BD Trucount beads.
Statistics
The impact of lymphocyte reconstitution on transplant outcome was analyzed in univariate manner by categorizing subset counts at different time points and calculating probabilities of survival, disease relapse and TRM using Kaplan-Meier or cumulative incidence models. Estimated survival and cumulative incidence rates were compared by log-rank and Gray's test, respectively. On the basis of published data, the cutoff for NK cells was set at 150 cells/ mL, 7 whereas cutoffs for CD4-and CD8-T-cells and B-cells were set at 200 cells/mL.
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The correlation between lymphocyte counts and transplant outcome was further analyzed in multivariable Cox models, into which the lymphocyte subset counts were entered as time-varying covariates. Cox models were adjusted for type of disease, disease stage, type of conditioning regimen, patient age, Karnofsky's performance status scale and presence of acute graft-vs-host disease (coded as a time-dependent covariate). In models with relapse as the end point, treatment with a calcineurin inhibitor (CNI) was additionally coded as a time-dependent covariate, in order to determine a possible interaction of pharmacological immunosuppression with lymphocyte recovery.
Results
Of the 345 patients, 211 were alive at last contact with a median follow-up of 3.7 years. Survival rates were similar for patients undergoing myeloablative or non-myeloablative conditioning regimens (5 year survival 55 ± 4% after myeloablative, 60±6% after non-myeloablative conditioning, P ¼ 0.20). Rates of TRM were similar in both cohorts with 18 and 20% after ablative and non-ablative conditioning, respectively (P ¼ 0.93), as were rates of disease relapse (30 and 29%, P ¼ 0.72).
Lymphocyte reconstitution kinetics were comparable after myeloablative and non-ablative conditioning regimens. Mean lymphocyte counts for CD3 þ /CD8 þ T-cells, CD3 þ /CD4 þ T-cells, CD3À/CD56 þ NK cells and CD19 þ B-cells are shown in Figure 1 for patients undergoing myeloablative or non-myeloablative transplantation. Statistically significant correlations were found between lymphocyte subsets at all time points (data not shown). On analyzing transplant-associated factors influencing the recovery of lymphocyte subsets, we found no significant impact of disease, conditioning regimen or patient sex. Advanced patient age negatively impacted on the recovery of CD4 T-cells (age at transplant 440 vs o40 years, P ¼ 0.03). No age effect was noted for the other lymphocyte subsets analyzed.
Lymphocyte subset reconstitution and disease relapse In this cohort of patients undergoing T-cell replete transplantation, we could not reproduce the previously described protective effect of rapid lymphocyte (and particularly NK cell) reconstitution at 1 month after transplantation (relapse in patients with day 30 NK cells 4150/mL: 30±5% vs 36±6% in patients with day 30 NK cells o150/mL, P ¼ 0.71). No significant differences were either detected for NK cell counts on days 90 and 180 (P ¼ 0.64 and 0.63, respectively). In contrast, NK cells 4150/mL 12 months after transplantation conferred a strong protection from relapse (relapse rate 4 ± 3% vs 17 ± 5%, P ¼ 0.01). Relapses beyond 24 months after transplantation were too rare to distinguish any significant difference (3% in patients with either 4or o150 NK cells/mL). Rates of disease relapse in patients with NK cells above or below the 150/mL cutoff are shown in Figure 2 . No other lymphocyte subset had any statistically significant impact on the rate of disease relapse on any time point analyzed after transplantation (data not shown). CD4 T-cell counts at time of transplant showed a borderline significant association with transplant outcome, with patients carrying more CD4 T-cells doing better (P ¼ 0.05). After correcting for disease stage, this association disappeared, suggesting that CD4 lympocytopenia pretransplant acted as a pure surrogate marker for advanced disease stage. The survival advantage of patients with high NK cells counts 1 year post transplant stemmed mainly from patients treated with myeloablative conditioning (relapse rates 2 ± 2% vs 22 ± 7%, P ¼ 0.003). A similar trend was observed after non-myeloablative conditioning (relapse rates 0 ± 0% vs 5 ± 5%), however, the difference did not reach statistical significance (P ¼ 0.09) because of the low number of late relapses after this type of transplant.
As protective effects of high numbers of NK cells after allogeneic transplantation have previously been described, after transplantation for myeloid malignancies, we performed subgroup analyses of patients stratified by their disease type. However, in patients with myeloid disease, the rate of late relapse (41 year after transplantation) was low for both patients with NK cell counts above or below 150/ mL at day 365 (3 ± 2% vs 10 ± 6%, P ¼ 0.59). In contrast, late relapse was more frequently seen in patients with lymphatic disease, and within this population, a significant protection from disease relapse could be demonstrated for patients with lymphoma or myeloma as underlying disease (6 ± 6% vs 32 ± 13%, P ¼ 0.02), whereas no significant protection from relapse was evident for patients transplanted for acute lymphoblastic leukemia (0±0% vs 14 ± 14%, P ¼ 0.19).
Protection from disease relapse associated with high numbers of circulating NK cells was found at a much later time point in this cohort than previously described. As patients in our cohort were treated with CNIs during the first 6-12 months post transplant (and longer in case of graft-vs-host disease), we speculated that the NK cell effects on disease relapse might only operate after discontinuation of CNI treatment. However, when CNI treatment was added to the Cox model as a time-dependent covariate, we found no interaction between CNI treatment and NK cell count (P ¼ 0.96).
Lymphocyte subset reconstitution and TRM At day 30, none of the lymphocyte subsets showed a statistically significant influence on TRM, although there was a trend to lower TRM rates for patients with NK cell counts 4150/mL at that time point (TRM 7±2% vs 14±4% for patients with NK cells o150/mL, P ¼ 0.18). This difference became statistically significant on day 90 (TRM 4 ± 2% vs 12±3%, P ¼ 0.03) and on day 180 (TRM 2±1% vs 12±4%, P ¼ 0.02). No further significant protection from TRM was seen at time points 12 and 24 months after transplantation. A protective effect of similar magnitude was seen for patients with high CD4 T-cell counts at the 1, 3 and 6 months post transplant time points (TRM for patients with 4200 vs those with o200 cells/mL of: 6 ± 2% vs 15 ± 4%, P ¼ 0.07; 4 ± 2% vs 13 ± 4%, P ¼ 0.01; 2 ± 1% vs 15 ± 5%, P ¼ 0.002, respectively). Rates of TRM at different time points are depicted in Figure 2 for patients with low and high numbers of NK cells and CD4 T-cells. CD8 T-cells and B-cells had no significant effect on the TRM rates at any time point. As NK cells have been shown to be important effectors of antimicrobial immunity, we speculated that the beneficial effect of high numbers of NK cells might be because of protection from infectious mortality. However, the direct cause of death in patients after SCT is notoriously difficult to determine, and in our cohort, death was directly attributed to infection in 16 patients, a cohort too small to perform any meaningful analysis on a possible protective effect of high numbers of NK cells.
Multivariable analyses
To corroborate the results of univariate analyses, we used multivariable Cox models with time-dependent covariates. Regarding disease relapse, NK cell counts coded as a categorized, time-dependent covariate covering the whole post transplant time period did not convey significant protection from disease relapse (hazard ratio (HR) for NK cells 4150/mL ¼ 0.73, 95% confidence interval (95% CI) 0.44-1.20, P ¼ 0.21). As patients transplanted for multiple myeloma or lymphoproliferative disorder had shown the greatest benefit in univariate analysis, this group was analyzed in the Cox model as well. The protection was more pronounced in this population, but did not reach statistical significance (HR 0.56, 95% CI 0.19-1.70, P ¼ 0.31).
In the analysis with TRM as end point, a high number of NK cells was confirmed as a protective factor when analyzed as a variable covering the entire post transplant period (HR 0.43, 95% CI 0.2-0.90, P ¼ 0.03). After correction for confounding parameters, the degree of protection in patients with 4150 NK cells/mL blood remained virtually unchanged (HR 0.45, 95% CI 0.21-0.95, P ¼ 0.03). Importantly, the protective effect of high NK cell count was independent from that seen for high numbers of CD4 T-cells (HR 0.37, 95% CI 0.19-0.74, P ¼ 0.005), arguing against a role of NK cell number as a mere surrogate marker for T-cell reconstitution. Detailed results of this adjusted analysis are given in Table 2 .
Discussion
In this study, we aimed to analyze the correlation of lymphocyte subset recovery with outcome after T-cell replete allogeneic hematopoietic SCT (HSCT). In contrast to patient series treated with T-cell depleted HSCT, wherein a strong correlation between early lymphocyte recovery (in particular, early NK cell recovery) has been associated with protection of disease relapse and improved survival, we could not demonstrate any protective effect of high NK cell counts at 1, 3 or 6 months after transplantation. None of the other subsets analyzed (CD8 T-cells, CD4 T-cells and B-cells) had any measurable effect either. In contrast, a strong protection from disease relapse was seen for patients with 4150 NK cells/mL blood at the 12-months post transplant time point. Protection was most prominent for patients transplanted for multiple myeloma or lymphoma (both diseases with in vitro susceptibility to lysis by NK cells), 12 whereas no significant protective effect was seen for patients transplanted for acute lymphoblastic leukemia, a disease resistant to NK cell alloreactivity). 13 Late relapse in patients with myeloid disorders (which are sensitive to NK cells) occurred too rarely to draw any conclusions with certainty.
All patients received pharmacological graft-vs-host disease prophylaxis with a CNI for at least 6 months post transplant. We hypothesized that the absence of early NK cell-based anti-tumor effects might be explained by CNI treatment, which has previously been shown to interfere with NK cell maturation.
14 However, when CNI therapy was included into the Cox model as a time-dependent covariate, it did not significantly modify the effect of NK cell counts on the risk of disease relapse, arguing against a role of the immunosuppressive treatment interfering with NK cell alloreactivity. The reason why NK cell alloreactivity occurs at a later time point after T-cell replete transplantation compared with T-cell-depleted transplants, therefore, remains unclear.
In addition to protection from disease relapse, high numbers of circulating NK cells were associated with a reduced rate of TRM. This protection was of similar magnitude as that associated with a CD4 T-cell count 4200/mL. Although NK cell recovery has not previously been shown to affect TRM rates, rapid recovery of CD4 T-cell immunity has been demonstrated to lower rates of TRM in various transplant settings. 11, 15 It is tempting to speculate that, similar to CD4 T-cells, high numbers of NK cells might protect from infectious complications, however the number of deaths attributed directly to infection was too low in this cohort to analyze this end point separately.
In conclusion, we show that, similar to the setting of T-cell depleted transplantation, NK cell reconstitution impacts on outcome after unmanipulated HSCT, with a role for NK cells in protection from disease relapse and from TRM. Importantly, the effect on TRM seemed to be independent from the protection associated with high numbers of CD4 T-cells, arguing for an independent NK cell effect and against a role of NK cells as a pure surrogate marker for rapid (T-cell) immune reconstitution.
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